tiprankstipranks
Advertisement
Advertisement
Kazia Therapeutics announces offering of ADS, warrants
PremiumThe FlyKazia Therapeutics announces offering of ADS, warrants
3d ago
Kazia Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Kazia Therapeutics initiated with a Buy at Canaccord
14d ago
Kazia Therapeutics initiated with a Buy at Canaccord on paxalisib potential
Premium
The Fly
Kazia Therapeutics initiated with a Buy at Canaccord on paxalisib potential
14d ago
Kazia Therapeutics initiated with a Buy at Lake Street
PremiumThe FlyKazia Therapeutics initiated with a Buy at Lake Street
3M ago
Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy
Premium
Ratings
Analyst Raises Kazia’s Price Target to $30 and Reiterates Buy on Strengthened Confidence in PI3K/AKT/mTOR Strategy
3M ago
Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth
Premium
Company Announcements
Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth
3M ago
Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer
PremiumThe FlyKazia Therapeutics appoints Sudha Rao as Chief Scientific Officer
5M ago
Kazia Therapeutics initiated with a Buy at Laidlaw
Premium
The Fly
Kazia Therapeutics initiated with a Buy at Laidlaw
5M ago
Kazia Therapeutics Licenses SETDB1 Epigenetic Platform to Bolster Oncology Pipeline
Premium
Company Announcements
Kazia Therapeutics Licenses SETDB1 Epigenetic Platform to Bolster Oncology Pipeline
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100